Needham & Company LLC reissued their hold rating on shares of Cresco Labs (OTCMKTS:CRLBF – Free Report) in a research report sent to investors on Monday, Benzinga reports.
A number of other research analysts have also recently weighed in on the stock. Wedbush raised their price objective on shares of Cresco Labs from $2.50 to $3.00 and gave the stock an outperform rating in a research note on Thursday, May 16th. Ventum Cap Mkts raised shares of Cresco Labs to a strong-buy rating in a research note on Friday, August 9th. Finally, Roth Capital raised shares of Cresco Labs from a hold rating to a strong-buy rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Cresco Labs currently has an average rating of Buy and a consensus target price of $2.63.
Check Out Our Latest Stock Analysis on CRLBF
Cresco Labs Trading Down 0.5 %
Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.15). Cresco Labs had a negative return on equity of 6.78% and a negative net margin of 20.32%. The business had revenue of $184.36 million for the quarter, compared to analysts’ expectations of $184.26 million. Equities analysts forecast that Cresco Labs will post -0.03 EPS for the current fiscal year.
Cresco Labs Company Profile
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Featured Articles
- Five stocks we like better than Cresco Labs
- How to Invest in Blue Chip Stocks
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Canadian Penny Stocks: Can They Make You Rich?
- Jeff Brown’s Exegesis AI Stock Picks
- How to Capture the Benefits of Dividend Increases
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.